Kornimate/medical-research-clean huggingface dataset:
diagnostic performance of 18-fdg pet-ct scores for the diagnosis of polymyalgia rheumatica

Conditions: Inflammatory Rheumatism; 18-FDG; Positron-emission Tomography

Summary: study of the diagnostic performance of 18-fdg pet scores in polymyalgia rheumatica and comparaison with others inflammatories diseases.

polymyalgia rheumatica is difficult to diagnostic because symptoms are non specific and many diseases can be differential diagnosis (cancer, infections, others rheumatisms...). pet-ct is more often used to help for diagnostic of inflammatory disease, and particularly inflammatory rheumatism. some scores have been described to harmonize the diagnosis of polymyalgia rheumatica. the aim of this study is to evaluate the diagnostic performance of 18-fdg pet scores in polymyalgia rheumatica and compared with others inflammatories diseases such as ankylosing spondylarthritis. this is a multicentric retrospective study.

Eligibility criteria:
inclusion criteria: * having 18-fdg pet-ct between 2012 and 2024 * diagnosis of inflammatory rheumatism by specialist doctor * adult without opposition to use there data for research * affiliate to social security system exclusion criteria: * refusal participation * patient under juridic protection

Keywords: polymyalgia rheumatica fdg pet diagnostic performance score
tace for hcc by tandem and idarubicin

Conditions: Hepatocellular Carcinoma (HCC)

Summary: dcbeads and lipiodol-transarterial chemoembolization (tace) of hepatocellular carcinoma (hcc) using doxorubicin result in about 50% objective response rate at 6 months (precision v study, lammer et al. cvir 2010) we previously demonstrated that idarubicin was the most effective drug on 3 hcc cell lines (boulin et al., anticancer drugs 2009). we tested idarubicin-loaded beads in a phase i trial (boulin et al., aliment pharmacol therapy 2012) and more recently in a prospective multicentric phase ii trial (idasphere ii, magna cum laude cirse 2017, b guiu et al.). this trial was stopped at interim analysis because the endpoint was reached. tandem beads are precisely calibrated, of small size, allowing the maximization of ischemic effects together with an optimal efficacy of the drug. we previously published that idarubicin was able to load fastly in tandem, with minimal modification of bead diameter and a very interesting releasing profile of the drug (guiu et al., jvir 2015). we used tandem combined with idarubicin in our practice for the treatment of hcc by tace (in-label use of beads and the drug). no clinical study (even retrospective) has been published so far with tandem-ida (except our first paper published in jvir in 2015, only 4 patients). here we propose to collect the retrospective data of patients treated by tandem-ida, to help to design a future multicentric randomized phase ii trial


Eligibility criteria:
inclusion criteria: hcc according to histological examination or barcelona criteria measurable targets according to mrecist v1.1 child a or b7 cirrhosis (without decompensation in the past 6 months) hcc not candidate to surgery or ablation age ≥ 18 years performance status 0 or 1 thrombocytes ≥ 50 000/mm3, neutrophil count≥ 1 000/mm3, creatininemia ≤ 150 µmol/l no cardiac failure exclusion criteria: follow-up \< 1month lobar/main portal venous thrombus prior treatment by systemic chemotherapy or radioembolization

Keywords: tace
safe emergency department discharge rate (seige)

Conditions: Acute Myocardial Infarction; Acute Coronary Syndrome

Summary: the siemens poc high sensitivity troponin-i test system is an in vitro diagnostic test for the quantitative measurement of cardiac troponin i (ctn-i) in fresh human capillary (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used by healthcare professionals at the point of care (poc) as well as in the clinical laboratory. the siemens poc high sensitivity troponin-i test system is to be used as an aid in the diagnosis of myocardial infarction (mi).

study purpose/objective: * evaluate the clinical performance of the siemens poc hs ctn-i test system for the diagnosis and rule out of ami in patients presenting to the emergency department in whom serial ctni measurements are obtained on clinical indication. * correlate the blood and plasma outcomes on the siemens poc hs ctn-i test system as function of the corresponding hematocrit (hct) values. hypothesis: the siemens poc hs ctn-i test system will offer an excellent diagnostic performance for acute myocardial injury and acute myocardial infarction, as well as expedite the risk stratification of patients for early discharge from the emergency department.

Eligibility criteria:
inclusion criteria: 1. presents to the ed, or ambulatory care center equivalent, with signs or symptoms suspicious of a possible acs event. 2. baseline ctn-i measurement and one additional ctn-i measurement at two hours after the first measurement. 3. at least one 12-lead electrocardiogram exclusion criteria 1. less than 21 years old 2. pregnancy 3. trauma 4. declines to participate or has indicated that their blood/ medical information cannot be used for investigational purposes 5. did not present through the ed 6. transferred from an outside hospital or clinic.

Keywords: troponin acute myocardial injury acute myocardial infarction siemens poc siemens poc atellica® vtli siemens poc hs ctn-i
prospective evaluation complementing investigation with acurate neo device

Conditions: Aortic Stenosis

Summary: the study collects real-world data of patients who were treated with the acurate neo tavi system and evaluates early and midterm clinical outcomes.

the study collects real-world data of patients who were treated with the acurate neo tavi system and evaluates early and midterm clinical outcomes.

Eligibility criteria:
inclusion criteria: * ≥18 years. * severe aortic stenosis with indication of implantation of aortic valve prosthesis in which an acurate neo device is implanted according to the indications for use. * has signed the patient informed consent form. exclusion criteria: * severe aortic stenosis without indication of implantation of aortic valve prosthesis in which an acurate neo device is implanted according to the indications for use.

Keywords: tavi valve
short term, high dose vitamin d supplementation in moderate to severe covid-19 disease

Conditions: Covid19

Summary: covid-19 caused by sars-cov-2 virus has affected the lives of millions of individuals globally and also severely strained the medical community. pre-symptomatic and asymptomatic sars-cov-2 positive individuals far outnumber the symptomatic ones or those with severe disease. the transmission potential of sars cov-2 is potentially greater than earlier viral outbreaks of sars-cov and mers-cov.routine measures of social distancing, personal hand hygiene and limited outdoor contact activities have shown benefits to limit corona virus infection. however, the role of vitamin d in sars-cov-2 infection is sparingly explored despite the knowledge of an immunomodulatory role and protective effect of vitamin d against viral infections. meta-analysis of five clinical trials of vitamin d supplementation found that those receiving vitamin d supplementation had fewer respiratory tract infections (odds ratio = 0.58 (95%ci, 0.42 - 0.81).any immune-modulatory effect of vitamin d is likely to be observed at levels which are considered higher than that required for normal bone metabolism.


Eligibility criteria:
inclusion criteria: 1. rt-pcr proven sars-cov-2 infection or computed tomography scan findings compatible with the covid19 disease (bilateral multifocal ground-glass opacities ≥50%) 2. moderate to severe covid-19 defined by pfr ratio of \<200 3. sofa score\>4 4. patients with vitamin d deficiency defined as 25 (oh)d level\<20 ng/ml 5. age\>18 years exclusion criteria: * 1. vitamin d sufficient or already receiving vitamin d supplements 2. active malignancy 3. hypercalcemia, hyperparathyroidism 4. chronic kidney disease (egfr\<30 ml/min) 5. pregnant and lactating women 6. patient on mechanical ventilation at icu admission
the impact of family financial support on parental mental health

Conditions: Financial Coaching; Mental Disorders; Social Determinants; Medical-Financial Partnership; Toxic Stress

Summary: the investigators have partnered with financial coaching organizations to establish what the investigators have termed a "medical-financial partnership (mfp)" that offers financial coaching to improve financial and mental health. the investigators will evaluate the mfp's impact on mental health using the kessler-6 emotional distress scale.

financial coaching is a new tool in the field of community development, but it has already demonstrated significant financial impact in a number of studies, including one randomized trial conducted by the urban institute. financial coaching improves participant financial literacy, budgeting, saving for financial emergencies, and debt level. the investigators' project will help clinicians and the field of community economic development understand health and well-being through a new economic lens and assess the health-related impacts of the emerging field of financial coaching. the investigators have partnered with financial coaching organizations to establish what they have termed a "medical-financial partnership (mfp)" that offers financial coaching to improve financial and mental health. the investigators will evaluate the mfp's impact on mental health using the kessler-6 emotional distress scale as the outcome variable. community-based participants will be recruited from south los angeles and randomized to receive either monthly financial coaching plus access to referral for social services (intervention) or access to referral for social services alone (control). inclusion criteria include having dependents under age 18, having some form of income, and having a tax identification number (social security number or individual tax identification number). participants will be surveyed quarterly regarding their mental health using the kessler-6 emotional distress scale.

Eligibility criteria:
inclusion criteria: * caregivers/parents with one or more child dependents, income of any sort, and a tax identification number. exclusion criteria: * inability to partake in financial coaching due to physical limitations or primary language other than spanish or english.

Keywords: financial coaching mental health social determinants medical-financial partnership toxic stress
diclofenac plus lidocaine gel for pain relief during intrauterine device insertion(iud).

Conditions: Pain

Summary: the aim of this study is to determine the effectiveness of a combination of diclofenac and lidocaine gel in reducing pain during iud insertion.

various studies evaluating the use of local anesthetics or misoprostol prior to iud insertion have mixed results.we think that the combination of diclofenac and lidocaine gel could be more successful in relieving pain during iud insertion than single therapy.the aim of this study is to determine the effectiveness of a combination of diclofenac and lidocaine gel in reducing pain during iud insertion.

Eligibility criteria:
inclusion criteria: * patients of reproductive age requesting iud for contraception exclusion criteria: * patients with contraindications to iud insertion ( less than 6 weeks postpartum, less than 2 weeks after abortion, uterine anomalies, fibroid distorting uterine cavity, pregnancy, pelvic inflammatory disease, cervicitis, uterine depth less than 6 cm or more than 9 cm) , previous iud insertion, allergy to diclofenac or lidocaine, peptic ulcer , asthma, bleeding disorders, cardiac, liver or kidney diseases.

Keywords: iud,diclofenac , lidocaine
the occurrence of emergence agitation in pediatric strabismus surgery

Conditions: Emergence Delirium; Strabismus; Pediatric ALL

Summary: the present trial conducted to demonstrate the administration of sugammadex as reversal of neuromuscular blockade agent reduces the incidence of emergence agitation (ea) comparing to neostigmine

ea is one of the most common postoperative complications in after general anesthesia in pre-school aged pediatric patients. there are several causes contributed to occurrence of ea such as postoperative pain, type of surgery and surgical site, hyperthermia or hypothermia. some researches showed that the occurrence of ea is associated with patients' anxiety and investigators of this trial inferred that patients' anxiety after general anesthesia could be related to ability to breathe. ability to breathe is highly associated with level of residual neuromuscular blockade (nmb) after recovery from general anesthesia. investigators evaluate the pediatric anesthesia emergence delirium (paed) scale to investigate whether sugammadex as reversal agents of nmb reduces the incidence of ea in pediatric patients who undergo strabismus surgery.

Eligibility criteria:
inclusion criteria: * patients scheduled elective strabismus surgery aged 4-7 with american society of anesthesiologists (asa) classification 1-3. exclusion criteria: * asa classification 3 or more * impaired liver function * impaired kidney function * myasthenia gravis or other neuromuscular disorders * history of drug allergy * cardiovascular disease or arrhythmia
study of jak3 inhibitor for the prevention of acute rejection in kidney transplant patients

Conditions: Kidney Transplantation

Summary: a new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called jak3, is being developed by pfizer to prevent transplant rejection. in this research study, a jak3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.


Eligibility criteria:
inclusion criteria: * recipient of first time kidney transplant * between the ages of 18 and 70 years, inclusive exclusion criteria: * recipient of any non-kidney transplant

Keywords: immunosuppression, jak3 inhibitor, kidney transplantation
observational study of kibow biotics in chronic kidney failure patients

Conditions: Chronic Kidney Failure

Summary: a specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "enteric dialysistm". however, it is also referred to as enteric toxin reduction technology. our hypothesis is to assess the potential benefits in devising a bowel-based probiotic formulation (kibow® biotics/renadyltm) as a dietary supplement product for patients undergoing standardized care of treatment for their ckd stage 3 and stage 4 conditions.

probiotics are increasingly utilized clinically. as their safety and health benefits are established, it is reasonable to anticipate that probiotic bacteria will be incorporated into a growing number of clinical regimens, as a dietary supplement. extensive in vitro r\&d investigations in kibow's laboratories bacterial strains studied were a mixture of patented and proprietary strains of streptococcus thermophilus (kb27), lactobacillus acidophilus (kb31) and bifidobacterium longum (kb35). oral administration of these bacterial formulations, tested in the 5/6th nephrectomized rat model (at thomas jefferson university, phila., pa) and minipig model (at indiana university, indianapolis, in), decreased both blood urea nitrogen (bun) and serum creatinine (scr) levels. two independent veterinarians investigated the effect of kibow biotics® in cats and dogs (of both genders and varying body weights) with moderate to severe kidney failure. based on positive results, this formulation, marketed and distributed as azodyltm, is currently licensed for veterinary applications to vetoquinol usa. pilot scale studies, double blind, placebo controlled, cross-over studies for six months conducted in 45 patients in usa, canada, argentina, and nigeria demonstrates reduction of bun (p\>95%) and improved quality of life (p\>95%). decrease in creatinine and uric acid levels were also observed. however, these studies were based on correlating the age of geriatric cats and dogs with moderate to significant kidney failure to human geriatric conditions. the proposed current study is being reevaluated based on correlating the weight basis of animal to human conditions. hence, this is a does escalation study on ingestion of 1x (90 billion cfu/day), 2x (180 billion cfu/day), and 3x (270 billion cfu/day) dosages.

Eligibility criteria:
inclusion criteria: * age 18 to 75 years * ckd stages 3 and 4 as documented by prior medical history * serum creatinine \>2.5 mg/dl * stable and on ckd status 3 and 4 at least for a year or more exclusion criteria: * pregnant or nursing women * refusal to sign the informed consent form * documented to have hiv/aids/liver disease * active dependency on drugs or alcohol * any non-related medical, debilitating disease/disorder that would interfere with adherence to this study * currently on anticoagulant therapy

Keywords: chronic kidney failure stage three and four probiotics kibow biotics dialysis gut based uremic toxin removal
study in stabilized schizophrenic patients to evaluate the pharmacokinetics of risperidone and 9-hydroxy (oh)-risperidone when risperidone is administered from a polyurethane implant

Conditions: Schizophrenia; Schizo-affective Disorder

Summary: the study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of risperidone and 9-oh-risperidone following implantation of two or three, 300 mg risperidone implants.

the study will be a 6-month, open-label, study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of risperidone and 9-oh-risperidone following implantation of two or three, 300 mg risperidone implants. subjects who are diagnosed with schizophrenia or schizoaffective disorder according to dsm-v and are stable on a daily 4 mg oral dose of risperidone for at least 8 weeks will be recruited into the study. subjects stable on a 4 mg oral dose of risperidone will be implanted with two or three, 300 mg, risperidone implants. all implants will be placed in the inner aspect of the upper arm. plasma concentrations of risperidone and the active moiety will be measured prior to placement of the risperidone implants, throughout the implantation period, and after re-converting to oral risperidone following the removal of the risperidone implants.

Eligibility criteria:
inclusion criteria: 1. subject (and/or a subject's authorized legal representative) has provided written informed consent 2. patient meets the following criteria: * outpatient status * panss total score ≤ 80 at screening and if panss score at baseline is ≥ 20% change from screening, the patients cannot participate in the study. * a score of ≤ 3 on the following panss items: * conceptual disorganization * suspiciousness * hallucinatory behavior * unusual thought content 3. subject is male or female between 18 to 60 years of age 4. subject has a diagnosis of schizophrenia or schizoaffective disorder according to diagnostic and statistical manual of mental disorders, 5th edition (dsm-v) criteria exclusion criteria: 1. hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the investigator 2. subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide 3. has a current or recent (within 12 months) dsm-v diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening. 4. have impaired hepatic (alt/ast \>1.5 times higher than the upper limit of normal) or renal function (egfr\<50 ml/min) 5. previously defined hypersensitivity to risperidone 6. history of neuromalignant syndrome (nms) 7. electroconvulsive therapy within 6 months of admission 8. requires current use of agents that are strong inhibitors and inducers of cytochrome p450 2d6
the effectiveness of two anti-hiv treatments in hiv-infected patients

Conditions: HIV Infections

Summary: to determine the effects of zidovudine (azt) alone and in combination with didanosine (ddi) on viral load in the lymphoid tissue and blood of antiretroviral-naive, hiv-infected patients with cd4 counts greater than or equal to 550 cells/mm3. recent studies have shown that during the asymptomatic phase (clinical latency) of hiv infection, there is an extraordinarily large number of infected cd4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. these findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period.

recent studies have shown that during the asymptomatic phase (clinical latency) of hiv infection, there is an extraordinarily large number of infected cd4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. these findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period. patients are randomized to receive azt alone, azt plus ddi, or no therapy (placebo) daily for 48 weeks. patients are followed at weeks 2, 4, and 8, and then every 8 weeks thereafter until week 48.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * antibiotics for bacterial infections as clinically indicated. * recombinant erythropoietin (epo) and g-csf as clinically indicated for grade 3 or worse anemia and neutropenia, respectively. * antipyretics. * analgesics. * allergy medications. * oral contraceptives. * nonprescription medications such as vitamins or herbal therapies. concurrent treatment: allowed: * radiation therapy to local lesion only. * acupuncture. patients must have: * hiv seropositivity. * cd4 count \>= 550 cells/mm3. * no arc or aids conditions by cdc criteria. * consent of parent or guardian if less than 18 years of age. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * presence of factors predisposing to pancreatitis such as active alcoholism. * other medical conditions that would interfere with study compliance. concurrent medication: excluded: * other antiretrovirals or systemic immunomodulators. * systemic corticosteroids. * systemic cytotoxic chemotherapy. * intravenous pentamidine. concurrent treatment: excluded: * radiation therapy except to local lesion. patients with the following prior conditions are excluded: * history of chronic diarrhea, defined as more than four loose or watery stools on average daily for the past month. * history of grade 2 or worse peripheral neuropathy. * history of pancreatitis. * bacterial infection requiring antibiotics within 14 days prior to study entry. prior medication: excluded: * prior hiv therapy with antiretrovirals or systemic immunomodulators. prior treatment: excluded within 2 weeks prior to study entry: * transfusion. active substance abuse or alcoholism.

Keywords: didanosine drug therapy, combination zidovudine